Navigation Links
Pharmaceutical Key Trends 2011 - Biosimilar Market Overview
Date:10/24/2011

NEW YORK, Oct. 24, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceutical Key Trends 2011 – Biosimilar Market Overview

http://www.reportlinker.com/p0487117/Pharmaceutical-Key-Trends-2011-–-Biosimilar-Market-Overview.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

Introduction

In 2009, the combined biosimilars market size for the US and five major European markets was $150m. With more than 30 branded biologics with sales of $51bn set to lose patent exclusivity between 2011 and 2015, Datamonitor forecasts that the global biosimilar market will grow from $243m in 2010 to $3.7bn in 2015.

Features and benefits

* Overview of the biosimilar market, with biosimilar definitions in the US, EU and Japan, plus historical and forecast biosimilar sales out to 2015.

* Insight into the key drivers and resistors to biosimilar uptake in the developed and emerging markets.

* Assesses key factors determining successful biosimilar market access, and examines the major biosimilar players and the strategies they implement.

* Analyses biosimilar uptake in the five main European markets and provides insight into the future opportunities for biosimilar players.

Highlights

Due to their complexity, cost, and development risks, biosimilar production and commercialization in developed markets is concentrated among only a handful of pharma companies, all of which are established generics players.

Despite the Introduction of approval pathways in the US, EU, and Japan, the growing use of biologics, and the need for more cost-effective treatments, all of which help drive biosimilar uptake, there remain a large number of barriers to uptake.

There are relatively few factors which limit the growth of the biosimilar industry in the developing markets, although the Introduction of biosimilar pathways will restrict market access to many domestic biosimilar players, while low purchasing power and a high proportion of out-of-pocket expenditure, coupled with brand loyalty, limit access.

Your key questions answered

* Evaluate the evolving regulatory environment in the US, EU and Japan, and how this impacts biosimilar market access and uptake.

* Gain insight into the deal types among branded, generic and biosimilars players to either enter or bolster their position in the biosimilars market.

* Identify which branded biologics are facing patent expiry and provide significant opportunities for biosimilar developers.

Executive Summary

Introduction

Strategic scoping and focus

Key findings

Related reports

Upcoming related reports

2. GLOBAL BIOSIMILAR MARKET SIZE

[Missing title]

Biosimilar definitions

Biosimilar sales in 2009

Biologic sales exposed to potential biosimilar competition during 2011–15

Forecast biosimilar sales, 2010–15

Profitability of biosimilars versus branded biologics and generics

3. DRIVERS AND RESISTORS TO BIOSIMILAR UPTAKE

Drivers and resistors to biosimilar uptake in the developed markets

Drivers of biosimilar uptake in developed markets

Neutral factors impacting biosimilar uptake in developed markets

Resistors to biosimilar uptake in developed markets

Drivers and resistors to biosimilar uptake in Brazil, Russia, India, and China

Drivers of biosimilar uptake in emerging markets

Resistors impacting biosimilar uptake in emerging markets

4. BIOSIMILAR MARKET ACCESS

Key factors in determining the success of biosimilar market access

Biosimilar development timeline

Biosimilar development costs

Pros and cons of developing and manufacturing biosimilars in developing markets

Biosimilar approval pathways

Biosimilar producers face a challenging patent environment

Biosimilar pricing in developed markets

Partnerships help drive growth of the biosimilars industry

5. KEY BIOSIMILAR PLAYERS

Key biosimilar players in the developed and emerging markets

Key biosimilar players in the developed markets

Key players in the emerging markets

6. BIOSIMILARS BY GEOGRAPHIC MARKET

Biosimilar launches

US biosimilars market

Biosimilars in the five major EU markets

Japanese biosimilars market

Australian biosimilars market

BRIC biosimilars market

7. BIOSIMILAR UPTAKE

Uptake of biosimilar somatropin, filgrastim and epoetin

Biosimilar somatropin

Biosimilar filgrastim

Biosimilar epoetin

8. OPPORTUNITIES FOR THE BIOSIMILAR INDUSTRY

Branded biologic patent expiries present opportunities for the biosimilar industry

Biologic patent expiries in the US

Biologic patent expiries in the five major EU markets

Biologic patent expiries in Japan

Biosimilars in development internationally

Biosimilar MAbs and second-generation biosimilars offer the greatest commercial potential

9. BIBLIOGRAPHY

Publications and online articles

APPENDIX

Exchange rates used in this report

To order this report:

: Pharmaceutical Key Trends 2011 – Biosimilar Market Overview

More Market Research Report

Check our Real Time Industry Data

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaSecure, an Innovator in Pharmaceutical Serialization, Closes $3.9M Investment by Eric Schmidts Innovation Endeavors, Gray Ghost Ventures, Healthtech Capital and the TEEC Angel Fund
2. S1 Pharmaceuticals Appoints Robert Taylor Segraves, MD, PhD, and Robert Pyke, MD, PhD to Its Scientific Advisory Board
3. Valeant Pharmaceuticals to Announce 2011 Third Quarter Results on November 3, 2011
4. Robbins Umeda LLP Announces an Investigation of KV Pharmaceutical Company
5. Cumberland Pharmaceuticals Ranks as one of the Fastest Growing Companies in North America on Deloittes 2011 Technology Fast 500™
6. Onyx Pharmaceuticals Announces Third Quarter 2011 Financial Results Teleconference and Webcast
7. Jazz Pharmaceuticals Announces Third Quarter 2011 Results Conference Call on November 1
8. Arrien Pharmaceuticals Appoints Dr. Philip LoGrasso to its Scientific Advisory Board for CNS/Neurodegenerative Diseases
9. Critical Alerts For Intel, Mosaic, Deckers, Foot Locker, and Jazz Pharmaceuticals Released By Seven Summits Research
10. Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl
11. Amylin Pharmaceuticals Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):